3
Announcements
Trials
Browse
Landscape
Phase
Phase 4
1
Phase 2
1
Status
Terminated
1
Completed
1
Sponsor Class
INDUSTRY
2
Study Type
Interventional
2
Sponsor
Cancer Type
Genitourinary
2
Conditions
Prostatic Neoplasms
67
Neoplasm Metastasis
6
Prostatic Neoplasms, Castration-Resistant
4
Metastatic Castration-resistant Prostate Cancer
4
Neoplasms
3
Prostate Cancer Metastatic
2
Metastatic Castration Resistant Prostate Cancer
2
Breast Neoplasms
2
Parkinson Disease 4, Autosomal Dominant Lewy Body
1
Newly Diagnosed Oligometastatic Prostate Cancer
1
Metastatic Castration-sensitive Prostate Cancer
1
Hyperaldosteronism
1
Castration-resistant Prostate Cancer
1
Castrate-resistant Prostate Cancer
1
Adenocarcinoma
1
Interventions
enzalutamide
3
cabazitaxel
3
Prednisone
3
Docetaxel
2
Abiraterone Acetate
2
rucaparib
1
Zuclomiphene
1
XRP6258
1
Standard of Care
1
LY3023414
1
Injections
1
Abituzumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Has results
×
Prostate Cancer Metastatic
×
Abiraterone Acetate
×
Clear all
NCT02485691
2022-05-27
CARD
Sanofi
Phase 4
Completed
255 enrolled
21 charts
NCT02379390
2019-06-21
PRIMCAB
Sanofi
Phase 2
Terminated
8 enrolled
8 charts